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Clopidogrel Is Not Associated With Major Bleeding Complications
During Peripheral Arterial Surgery
David H. Stone, MD, Philip P. Goodney, MD, Brian W. Nolan, MD,
Andres Schanzer, MD, Donald S. Likosky, PhD, Julie Adams, MD, William
Tanski, MD, Daniel B. Walsh, MD, and Jack L. Cronenwett, MD, Dart-
mouth-HitchcockMedical Center, Lebanon, NH,Worcester, MA, Burling-
ton, VT, and Concord, NH
Objectives: Persistent variation in practice surrounds preoperative
clopidogrel (Plavix) management at the time of vascular surgery. Although
some surgeons preferentially discontinue clopidogrel, citing a perceived risk
of perioperative bleeding, others will proceed with surgery in patients taking
clopidogrel. The purpose of this study was to determine whether preopera-
tive clopidogrel use was associated with significant bleeding complications
during peripheral arterial surgery.
Methods:We reviewed a prospective regional vascular surgery registry
(VSGNE) of 66 surgeons from 12 centers in New England from 2003-
2009. Preoperative clopidogrel use 48 hours of surgery was analyzed
among patients undergoing carotid endarterectomy (CEA), lower extremity
bypass (LEB), endovascular abdominal aortic aneurysm repair (EVAR), and
open abdominal aortic aneurysm (AAA) repair. End points included postoper-
ative bleeding requiring reoperation as well as blood transfusion. Statistical
analysis was performed using Fisher exact and Wilcoxon rank sum tests.
Results:During the study interval, 5264 patients underwent CEA, 2883
underwent LEB, 1153 underwent EVAR, and 1330 underwent open AAA
repair, in whom 16.2%, 9.0%, 6.9%, and 4.6% were maintained on clopidogrel,
respectively. Reoperation for bleeding was not significantly different among
patients taking clopidogrel vs patients not taking clopidogrel at the time of
surgery across all operation categories. There was no difference in the incidence
of transfusion among treatment groups for all types of operation (Table). In
addition, among patients who did require transfusion, there was no significant
difference between clopidogrel-treated and non-clopidogrel-treated groups in
the mean units of packed red blood cells required (Table).
Conclusions: Patients undergoing peripheral arterial surgery in whom clo-
pidogrel was continued did not have significant bleeding complications compared
with patients not on clopidogrel. These data provide reassurance that clopidogrel
can safely be continued preoperatively in patients with important indications for its
use, such as symptomatic carotid disease or recent drug-eluting cardiac stents.
Standardized Angioplasty and Stenting Techniques for SFA-Popliteal
TASC C and D Lesions Improve Outcomes: A Prospective Evaluation
ManishMehta, MDMPH, Philip S. K. Paty, MD, Sean P. Roddy, MD, Paul
B. Kreienberg, MD, Yaron Sternbach, MD, John B. Taggert, MD, Kathleen
J. Ozsvath, MD, John W. Byrne, MD, Benjamin B. Chang, MD, Dhiraj M.
Shah,MD, and R.ClementDarling III,MD,TheVascularGroup, Albany,NY
Objectives: This study evaluated whether standardization of superficial
femoral-above knee popliteal artery (SFA-AK-PA) percutaneous angioplasty
and stenting (PTAS) improves outcomes when treating TASC C and D lesions
Methods: From 2004-2009, 698 patients with symptomatic infraingui-
nal SFA-AK-PA TASC-C/D lesions who underwent PTAS or bypass were
divided into three groups: standardized PTAS technique (n  213, 31%) vs
nonstandardized PTAS technique (n  179, 26%) vs Fem-AK-Pop PTFE
bypass (n 306, 43%). The standardized technique included (1) initial subin-
timal angioplasty with higher balloon pressures (range, 20-25 atm), (2) 20%
balloon oversizing, (3) routine use of self-expanding stents after angioplasty, (4)
minimum stent-stent overlap of1 cm, and (5) treatment of all moderate and
severe SFA/popliteal occlusive disease. The nonstandardized technique and
802Fem-AK-Pop PTFE bypass included most routine approaches used today, not
adhering to the standardization. Patients were followed-up at 1 month, 3
months, and at 6-month intervals with duplex ultrasound imaging, PVR, and
clinical examination. Data were prospectively collected. The SVS criteria were
used to define patency.
Results: Table
Conclusions: Even with longer lesion lengths, the standardized PTAS
technique for SFA-AK-PA occlusive disease has superior 1-, 2-, and 3-year primary
patency compared with the routine nonstandardized techniques or Fem-AK-Pop
PTFE bypasses. A randomized prospective multicenter trial comparing standard-
ized and nonstandardized percutaneous techniques is needed.
Variable
Standardized
technique
Nonstandardized
technique
Fem-AK Pop
PTFE bypass P
Patients, No. (%) 213 (31) 179 (26) 306 (43) .05
Claudication, No.
(%)
126 (59) 93 (52) 116 (38) .05
Rest pain/tissue
loss, No. (%)
87 (41) 86 (48) 190 (62) .05
Lesion length,
mean cm
26.5 16.1 NA .05
TASC II-D
lesions, No.
(%)
117 (55) 47 (26%) 187 (61) .05
Primary patency,
%
.05
1 year 95 76 81
2 years 86 64 73
3 years 78 52 62
Secondary
procedures,
No. (%)
66 (16.8) 66 (16.8) 47 (15.4) NS
Lower Extremity Revascularization (LER) in Young Patients: Have
Endovascular Options Impacted Practice and Outcomes?
Cassius Iyad N. Ochoa Chaar, MD, Steven Leers, MD, Luke Marone, MD,
Jae Cho, Donald T. Baril, MD, Nathan Fernandez, MD, Geetha Jeyabalan,
MD, Robert Y. Rhee, MD, Michel S. Makaroun, MD, and Rabih A. Chaer,
MD, University of Pittsburgh Medical Center, Pittsburgh, Pa
Objectives: This study assessed outcomes and utilization of revascular-
ization options in young patients with premature vascular disease.
Methods: A retrospective comparison of LER outcomes from 2000-
2008 was performed between consecutive patients aged 50 years
(group A) at the time of revascularization and control groups B (51-60
years) and C (60 years) of selected patients with comparable indications
and procedures. Kaplan-Meier curves and logistic regression analyses
were applied to patency, limb salvage, and survival on limb level or
patient level, as indicated.
Results: A total of 409 limbs in 298 patients (Table) were treated for
claudication (44%) or critical limb ischemia (CLI; 56%). Patients in group A
were more likely to be smokers and have a hypercoagulable state but were
less likely to have diabetes and renal failure. Indications for treatment were
comparable among groups, with nearly half of all procedures endovascular in
nature. Two perioperative deaths were both in group C (2%). Mean fol-
low-up was 29 months, with a remarkable 16% of claudicants in group A
progressing to CLI (B: 3.3%, C: 1.7%; P  0.001). Overall, 2-year primary,
primary-assisted, and secondary patency were significantly lower in group
A (51%, 65%, 68%) than in B (58%, 79%, 84%), and C (66%, 81%, 87%;
P  .045, .01, .001). Claudicants in group A, in particular, had lower
patency rates (Fig 1), with an unexpectedly low 2-year limb salvage rate
after intervention of only 90% (Fig 2). Results were more comparable
across groups for CLI. The 2-year freedom from reintervention was
similar among the three groups (A: 81%, B: 79%, C: 84%), irrespective of
the indication for intervention (P  NS). Younger patients had a
significantly higher 3-year survival (A: 90%, B: 85%) compared with
patients aged 60 (C: 71%; P  .005). The 2-year limb salvage rate was
significantly lower in claudicants in group A vs C undergoing endovas-
cular revascularization (P  .002), but not in patients treated with open
revascularization (P  NS). Predictors of loss of primary patency in-
cluded age 50 (P  .003), endovascular revascularization (P  .005),
